Ifrah N, Boucheix C, Marie J P, Innes J, Perrot J Y, Rio B, Cadiou M, Zittoun R
Cancer. 1986 Nov 1;58(9):2018-22. doi: 10.1002/1097-0142(19861101)58:9<2018::aid-cncr2820580911>3.0.co;2-6.
In a series of 22 adult acute lymphoblastic leukemias expressing the common acute lymphoblastic leukemia antigen (cALLA +), eight had marrow lymphocytosis greater than 30% (43 +/- 12%) with disappearance of marrow lymphoblasts and correction of bone marrow insufficiency at the end of the induction treatment. Four of these patients were studied for the cALL antigen at this time and had persistence of this immunological marker (62 +/- 15% of the mononuclear bone marrow cells). The evolution of these patients suggests that these patients were not in complete remission and emphasizes the usefulness of cALLA determination in cases with borderline excess of marrow lymphocytes.
在一组22例表达常见急性淋巴细胞白血病抗原（cALLA+）的成人急性淋巴细胞白血病中，8例骨髓淋巴细胞增多大于30%（43±12%），诱导治疗结束时骨髓原始淋巴细胞消失，骨髓功能不全得到纠正。此时对其中4例患者进行了cALL抗原研究，发现该免疫标志物持续存在（占骨髓单个核细胞的62±15%）。这些患者的病情演变表明他们并未完全缓解，这强调了在骨髓淋巴细胞略增多的病例中测定cALLA的有用性。
